A5011720511- Pharmacogenetics and Drug Metabolism
- Protease and Inhibitor Mechanisms
- Cell Adhesion Molecules Research
- Peptidase Inhibition and Analysis
- Pain Management and Opioid Use
- Blood Coagulation and Thrombosis Mechanisms
- Pharmaceutical studies and practices
- Biomedical Text Mining and Ontologies
- Pharmaceutical Practices and Patient Outcomes
- Cancer therapeutics and mechanisms
- Cancer, Stress, Anesthesia, and Immune Response
- PARP inhibition in cancer therapy
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Prostate Cancer Treatment and Research
- Research on Leishmaniasis Studies
- Neutropenia and Cancer Infections
- Health Sciences Research and Education
- Inflammatory mediators and NSAID effects
- Electronic Health Records Systems
- Opioid Use Disorder Treatment
- Transgenic Plants and Applications
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Protein Kinase Regulation and GTPase Signaling
- Signaling Pathways in Disease
- DNA Repair Mechanisms
University of South Florida
2025
Center for Drug Evaluation and Research
2024
United States Food and Drug Administration
2024
University of Chicago
2019-2022
University of Chicago Medical Center
2020-2022
Center for Personalized Cancer Treatment
2020-2022
PharmacoGenetics (China)
2020-2021
Virginia Commonwealth University
2017
Wichita State University
1996-2001
The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Several opioids have pharmacogenomic associations impacting analgesic efficacy. However, germline testing is not routinely incorporated into supportive oncology. We hypothesized that CYP2D6 profiling would correlate with opioid prescribing and hospitalizations.We analyzed 61,572 adult oncology patients from 2012 to 2018 for exposures. metabolizer phenotype (ultra-rapid [UM], normal [NM], intermediate [IM], or poor [PM]), the latter two of which may cause inefficacy codeine, tramadol,...
M.J.R., P.H.O., and K.D. are named as coinventors on a pending patent for the Genomic Prescribing System. M.J.R. is coinventor holding patents related to pharmacogenetic diagnostics receives royalties UGT1A1 genotyping. All other authors declared no competing interests this work. Please note: The publisher not responsible content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed corresponding author article.
Background: Many cancer patients who receive chemotherapy experience adverse drug effects. Pharmacogenomics (PGx) has promise to personalize dosing maximize efficacy and safety. Fluoropyrimidines irinotecan have well-known germline PGx associations. At our institution, we delivered clinical decision support (CDS) based on preemptively obtained genotyping results for a large number of non-oncology medications since 2012, but not previously evaluated the utility this strategy initiating...
Abstract The number of quantitative systems pharmacology (QSP) submissions to the U.S. Food and Drug Administration has continued increase over past decade. This report summarizes landscape QSP as December 2023. was used inform drug development across various therapeutic areas throughout process small molecular drugs biologics facilitated dose finding, ranging, optimization studies. Though majority (>66%) focused on effectiveness, also utilized simulate safety including liver toxicity,...
Objectives We built a novel mock pharmacogenomics web portal to deliver pharmacogenomic information and results patients. Utilizing patient focus group, we then sought understand insights on desired features of an effective portal. Methods The YourPGx Portal delivered four sample (omeprazole, simvastatin, clopidogrel, codeine). Patients from our existing institutional, prospective implementation study were recruited pilot the asked participate in group discussion led by two facilitators. All...
BACKGROUND In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, testing is not. This study hypothesizes that comprehensive profiling could have high relevance cancer care. METHODS Between January 2011 and August 2020, patients at University Chicago Medical Center were genotyped across custom panels reasons unrelated...
Our objective was to build a mock pharmacogenomic (PGx) patient portal and assess its ability disseminate test results information patients. The YourPGx Portal delivered four sample PGx (omeprazole, simvastatin, clopidogrel, codeine). We hosted two study groups knowledge perceptions of before after accessing the portal. Ten PGx-tested 10 traditional care participants were included (average 61 years, 60% women, 50% African American, 55% had bachelor's/advanced degree). Participants scored...
Applied pharmacogenomics presents opportunities for improving patient care through precision medicine, particularly when paired with appropriate clinical decision support (CDS). However, a lack of resources understanding pharmacogenomic test results may hinder shared decision-making and confidence in treatment. We sought to create education delivery platform complementary CDS system facilitate further research on the relevance pharmacogenomics.
Pharmacogenomics, which offers a potential means by to inform prescribing and avoid adverse drug reactions, has gained increasing consideration in other medical settings but not been broadly evaluated during perioperative care.
Cardiovascular diseases (CVDs) are notably prevalent among patients with obstructive sleep apnea (OSA), posing unique challenges in predicting CVD progression due to the intricate interactions of comorbidities. Traditional models typically lack necessary dynamic and longitudinal scope accurately forecast trajectories OSA patients. This study introduces a novel multi-level phenotypic model analyze interplay these conditions over time, utilizing data from Wisconsin Sleep Cohort, which includes...
Objectives Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions anesthesiologists, critical pain medicine providers would uncover unique considerations for future implementation within perioperative care. Methods A survey (multiple choice Likert-scale) was administered to our Department Anesthesia Critical Care prior initiation a department-wide prospective program. The addressed knowledge,...
12089 Background: Several opioid analgesics have well-known germline PGx associations which may predict either inefficacy or exaggerated (toxic) responses, depending on the patient’s genotype. Despite this, testing has not been routinely incorporated into oncology care. We hypothesized that CYP2D6 profiling offers potential to improve patients’ pain control by identifying individuals at increased risk for inadequate analgesia with standard dosing. Methods: retrospectively analyzed medication...